RESUMO
World Malaria Day 2015 highlighted the progress made in the development of new methods of prevention (vaccines and insecticides) and treatment (single dose drugs) of the disease. However, increasing drug and insecticide resistance threatens the successes made with existing methods. Insecticide resistance has decreased the efficacy of the most commonly used insecticide class of pyrethroids. This decreased efficacy has increased mosquito survival, which is a prelude to rising incidence of malaria and fatalities. Despite intensive research efforts, new insecticides will not reach the market for at least 5 years. Elimination of malaria is not possible without effective mosquito control. Therefore, to combat the threat of resistance, key stakeholders need to rapidly embrace a multifaceted approach including a reduction in the cost of bringing new resistance management methods to market and the streamlining of associated development, policy, and implementation pathways to counter this looming public health catastrophe.
Assuntos
Anopheles/fisiologia , Controle de Doenças Transmissíveis , Insetos Vetores , Resistência a Inseticidas , Mosquiteiros Tratados com Inseticida , Malária/prevenção & controle , Controle de Mosquitos , Piretrinas , África Subsaariana , Animais , HumanosRESUMO
It is important to realize that leishmaniasis guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The IDSA and ASTMH consider adherence to these guidelines to be voluntary, with the ultimate determinations regarding their application to be made by the physician in the light of each patient's individual circumstances.
Assuntos
Leishmaniose/diagnóstico , Leishmaniose/terapia , HumanosRESUMO
It is important to realize that leishmaniasis guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The IDSA and ASTMH consider adherence to these guidelines to be voluntary, with the ultimate determinations regarding their application to be made by the physician in the light of each patient's individual circumstances.
Assuntos
Leishmaniose/diagnóstico , Leishmaniose/terapia , HumanosRESUMO
BACKGROUND: There is a need for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect profile. METHODS: We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments containing 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tunisia. We randomly assigned 375 patients with one to five ulcerative lesions from cutaneous leishmaniasis to receive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, or vehicle control (with the same base as the other two creams but containing neither paromomycin nor gentamicin). Each lesion was treated once daily for 20 days. The primary end point was the cure of the index lesion. Cure was defined as at least 50% reduction in the size of the index lesion by 42 days, complete reepithelialization by 98 days, and absence of relapse by the end of the trial (168 days). Any withdrawal from the trial was considered a treatment failure. RESULTS: The rate of cure of the index lesion was 81% (95% confidence interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone, and 58% (95% CI, 50 to 67) for vehicle control (P<0.001 for each treatment group vs. the vehicle-control group). Cure of the index lesion was accompanied by cure of all other lesions except in five patients, one in each of the paromomycin groups and three in the vehicle-control group. Mild-to-moderate application-site reactions were more frequent in the paromomycin groups than in the vehicle-control group. CONCLUSIONS: This trial provides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major disease. (Funded by the Department of the Army; ClinicalTrials.gov number, NCT00606580.).
Assuntos
Gentamicinas/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Paromomicina/administração & dosagem , Administração Tópica , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Gentamicinas/efeitos adversos , Humanos , Análise de Intenção de Tratamento , Masculino , Pessoa de Meia-Idade , Pomadas , Paromomicina/efeitos adversos , Adulto JovemRESUMO
Individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency are at risk for the development of hemolytic anemia when given 8-aminoquinolines (8-AQs), an important class of antimalarial/antiinfective therapeutics. However, there is no suitable animal model that can predict the clinical hemolytic potential of drugs. We developed and validated a human (hu)RBC-SCID mouse model by giving nonobese diabetic/SCID mice daily transfusions of huRBCs from G6PD-deficient donors. Treatment of SCID mice engrafted with G6PD-deficient huRBCs with primaquine, an 8-AQ, resulted in a dose-dependent selective loss of huRBCs. To validate the specificity of this model, we tested known nonhemolytic antimalarial drugs: mefloquine, chloroquine, doxycycline, and pyrimethamine. No significant loss of G6PD-deficient huRBCs was observed. Treatment with drugs known to cause hemolytic toxicity (pamaquine, sitamaquine, tafenoquine, and dapsone) resulted in loss of G6PD-deficient huRBCs comparable to primaquine. This mouse model provides an important tool to test drugs for their potential to cause hemolytic toxicity in G6PD-deficient populations.
Assuntos
Anemia Hemolítica/diagnóstico , Transfusão de Eritrócitos/métodos , Deficiência de Glucosefosfato Desidrogenase/terapia , Primaquina/uso terapêutico , Aminoquinolinas/efeitos adversos , Aminoquinolinas/uso terapêutico , Anemia Hemolítica/sangue , Anemia Hemolítica/induzido quimicamente , Animais , Antimaláricos/efeitos adversos , Antimaláricos/uso terapêutico , Cloroquina/efeitos adversos , Cloroquina/uso terapêutico , Terapia Combinada , Dapsona/efeitos adversos , Dapsona/uso terapêutico , Relação Dose-Resposta a Droga , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Avaliação Pré-Clínica de Medicamentos/métodos , Contagem de Eritrócitos , Feminino , Deficiência de Glucosefosfato Desidrogenase/sangue , Humanos , Mefloquina/efeitos adversos , Mefloquina/uso terapêutico , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Primaquina/efeitos adversos , Pirimetamina/efeitos adversos , Pirimetamina/uso terapêutico , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Transplante HeterólogoRESUMO
BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly dosing in a human Plasmodium falciparum challenge model. METHODS: Thirty volunteers randomly received 1 of the following dose regimens: (1) 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) 1 day prior to infectious mosquito challenge (day -1), (2) 250/100 milligrams on day 4 after challenge, (3) 250/100 milligrams on day -7, (4) 500 milligrams of atovaquone and 200 milligrams of proguanil (500/200 milligrams) on day -7 or, (5) 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7. All regimens included matching placebo such that all volunteers received identical pill numbers. Six volunteers served as open-label infectivity controls. Volunteers underwent mosquito sporozoite challenge with P. falciparum 3D7 strain. Follow-up consisted of serial microscopy and close clinical monitoring for 90 days. RESULTS: Six of 6 infectivity controls developed parasitemia as expected. Two of 5 evaluable volunteers receiving 250/100 milligrams 7 days prior to challenge and 1 of 6 volunteers receiving 1000/400 milligrams 7 days prior to challenge were microscopically diagnosed with malaria. All other volunteers were protected. Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success). Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success). CONCLUSIONS: Single-dose atovaquone-proguanil provides effective malaria chemoprophylaxis against P. falciparum challenge at dosing intervals supportive of weekly dosing. Postexposure prophylaxis 4 days after challenge was 100% effective.
Assuntos
Antimaláricos/administração & dosagem , Atovaquona/administração & dosagem , Malária Falciparum/prevenção & controle , Plasmodium falciparum/efeitos dos fármacos , Proguanil/administração & dosagem , Adulto , Antimaláricos/efeitos adversos , Antimaláricos/farmacocinética , Área Sob a Curva , Atovaquona/efeitos adversos , Atovaquona/farmacocinética , Quimioprevenção/métodos , Estudos de Coortes , Combinação de Medicamentos , Feminino , Humanos , Malária Falciparum/tratamento farmacológico , Malária Falciparum/metabolismo , Masculino , Pessoa de Meia-Idade , Parasitemia/tratamento farmacológico , Parasitemia/metabolismo , Parasitemia/prevenção & controle , Placebos , Proguanil/efeitos adversos , Proguanil/farmacocinética , Esporozoítos/efeitos dos fármacosAssuntos
Doenças Assintomáticas/epidemiologia , Doenças Assintomáticas/terapia , Malária/epidemiologia , Malária/terapia , Anemia/diagnóstico , Anemia/epidemiologia , Anemia/terapia , Doença Crônica , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/epidemiologia , Transtornos Cognitivos/terapia , Humanos , Malária/diagnóstico , Resultado do TratamentoRESUMO
To help mitigate the expanding global impact of malaria, with its associated increasing drug resistance, implementation of prompt and accurate diagnosis is needed. Malaria is diagnosed predominantly by using clinical criteria, with microscopy as the current gold standard for detecting parasitemia, even though it is clearly inadequate in many health care settings. Rapid diagnostic tests (RDTs) have been recognized as an ideal method for diagnosing infectious diseases, including malaria, in recent years. There have been a number of RDTs developed and evaluated widely for malaria diagnosis, but a number of issues related to these products have arisen. This review highlights RDTs, including challenges in assessing their performance, internationally available RDTs, their effectiveness in various health care settings, and the selection of RDTs for different health care systems.
Assuntos
Malária/diagnóstico , Plasmodium/isolamento & purificação , Animais , Anticorpos Antiprotozoários/sangue , Antígenos de Protozoários/sangue , Humanos , Malária/prevenção & controle , Microscopia , Parasitologia/métodos , Parasitologia/normas , Plasmodium/imunologia , Kit de Reagentes para Diagnóstico , Sensibilidade e EspecificidadeRESUMO
In our laboratory, a series of antimicrobial peptides have been developed, where the resulting 3D-physicochemical properties are controlled by the placement of amino acids with well-defined properties (hydrophobicity, charge density, electrostatic potential, and so on) at specific locations along the peptide backbone. These peptides exhibited different in vitro activity against Staphylococcus aureus (SA) and Mycobacterium ranae (MR) bacteria. We hypothesized that the differences in the biological activity is a direct manifestation of different physicochemical interactions that occur between the peptides and the cell membranes of the bacteria. 3D-QSAR analysis has shown that, within this series, specific physicochemical properties are responsible for antibacterial activity and selectivity. There are five physicochemical properties specific to the SA QSAR model, while five properties are specific to the MR QSAR model. These results support the hypothesis that, for any particular AMP, organism selectivity and potency are controlled by the chemical composition of the target cell membrane.
Assuntos
Antibacterianos/química , Peptídeos Catiônicos Antimicrobianos/química , Relação Quantitativa Estrutura-Atividade , Sequência de Aminoácidos , Antibacterianos/farmacologia , Peptídeos Catiônicos Antimicrobianos/farmacologia , Membrana Celular/química , Fenômenos Químicos , Físico-Química , Análise por Conglomerados , Matemática , Modelos Moleculares , Conformação Molecular , Dados de Sequência Molecular , Mycobacterium/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Eletricidade EstáticaRESUMO
The evolution of drug-resistant bacteria is one of the most critical problems facing modern medicine and requires the development of new drugs that exhibit their antibacterial activity via novel mechanisms of action. One potential source of new drugs could be the naturally occurring peptides that exhibit antimicrobial activity via membrane disruption. To develop antimicrobial peptides exhibiting increased potency and selectivity against Gram positive, Gram negative, and Mycobacterium bacteria coupled with reduced hemolytic activity, peptides containing unnatural amino acids have been designed, synthesized, and evaluated. These compounds were designed on the basis of the electrostatic surface potential maps derived from the NMR determined SDS and DPC micelle-bound conformations of (Ala8,13,18)magainin-2 amide. Unnatural amino acids were incorporated into the polypeptide backbone to control the structural and physicochemical properties of the peptides to introduce organism selectivity and potency. The methods and results of this investigation are described below.
Assuntos
Aminoácidos/química , Antibacterianos/química , Peptídeos/química , Aminoácidos/farmacologia , Animais , Antibacterianos/farmacologia , Desenho de Fármacos , Farmacorresistência Bacteriana Múltipla , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Hemólise , Camundongos , Testes de Sensibilidade Microbiana , Modelos Moleculares , Peptídeos/farmacologia , Pele/lesões , Eletricidade Estática , Cicatrização/efeitos dos fármacosRESUMO
A series of acid-stable carboxamide derivatives of 2-guanidinoimidazolidinedione (5a-c and 6a-c) were prepared as potential malaria prophylactic and radical cure agents. The new compounds showed moderate to good causal prophylactic activity in mice infected with Plasmodium yoelii sporozoites. Three compounds were further tested for causal prophylactic activity in Rhesus monkeys infected with Plasmodium cynomolgi sporozoites, and all showed a delay in patency from 13 to 40 days at 30 mg/kg/day x 3 days by IM dosing. Two out of four compounds tested for radical curative activity in Rhesus showed cure at 30 mg/kg/day x 3 days. The other two compounds showed delay in relapse from 16 to 68 days. Conversion of new carboxamides (5 and 6) to s-triazine derivatives (7) was demonstrated in mouse and human microsomal preparations and in rat plasma. The results suggest the metabolites, s-triazine derivatives 7, may be the active species of the new carboxamides 5a-c and 6a-c prepared in this study.
Assuntos
Antimaláricos/síntese química , Guanidinas/síntese química , Imidazolidinas/síntese química , Malária/tratamento farmacológico , Malária/prevenção & controle , Animais , Antimaláricos/química , Antimaláricos/farmacologia , Guanidinas/química , Guanidinas/farmacologia , Humanos , Imidazolidinas/química , Imidazolidinas/farmacologia , Técnicas In Vitro , Camundongos , Microssomos Hepáticos/metabolismo , Plasmodium cynomolgi/efeitos dos fármacos , Plasmodium yoelii/efeitos dos fármacos , Ratos , Relação Estrutura-AtividadeRESUMO
Although efficacious forms of malaria chemoprophylaxis currently exist, many travelers to malaria-endemic areas fail to use them effectively. We suggest that taking antimalarial medications prior to travel may prevent more malaria by improving compliance. Treatment regimens of antimalarial drugs taken prior to travel could protect persons for up to one month of exposure. We urge additional testing of pre-travel malaria chemoprophylaxis regimens.
Assuntos
Antimaláricos/administração & dosagem , Malária/prevenção & controle , Viagem , Esquema de Medicação , HumanosAssuntos
Países em Desenvolvimento , Saúde Global , Malária/diagnóstico , Parasitologia/métodos , África/epidemiologia , África Subsaariana/epidemiologia , Animais , Antimaláricos/uso terapêutico , Criança , Pré-Escolar , Efeitos Psicossociais da Doença , Árvores de Decisões , Técnicas e Procedimentos Diagnósticos , Humanos , Lactente , Malária/tratamento farmacológico , Malária/epidemiologia , Malária Falciparum/diagnóstico , Malária Falciparum/tratamento farmacológico , Malária Falciparum/epidemiologia , Modelos Teóricos , Plasmodium falciparum/isolamento & purificaçãoRESUMO
To determine whether antibodies to the 19-kDa fragment of merozoite surface protein 1 (MSP1(19)) help to control blood-stage Plasmodium falciparum infection, we performed a rechallenge experiment of previously infected Aotus monkeys. Monkeys previously exposed to the FVO strain of P. falciparum that did or did not develop high antibody titers to MSP1(19) and malaria-naïve monkeys were challenged with erythrocytes infected with the same strain. Prepatent periods were prolonged in previously infected monkeys compared with malaria-naïve monkeys. Previously infected monkeys with preexisting anti-MSP1(19) antibodies showed low peak parasitemias that cleared spontaneously. Previously infected monkeys that had no or low levels of pre-existing anti-MSP1(19) antibodies also showed low peak parasitemias, but because of low hematocrits, all of these animals required treatment with mefloquine. All previously malaria-naïve animals were treated because of high parasitemias. The results of this study suggest that antibody to the 19-kDa carboxy-terminal fragment of MSP1 plays a role in preventing the development of anemia, an important complication often associated with malaria.
Assuntos
Anemia/imunologia , Anticorpos Antiprotozoários/imunologia , Malária Falciparum/imunologia , Proteína 1 de Superfície de Merozoito/imunologia , Doenças dos Macacos/parasitologia , Plasmodium falciparum/imunologia , Anemia/parasitologia , Anemia/patologia , Animais , Anticorpos Antiprotozoários/sangue , Antimaláricos/uso terapêutico , Aotidae , Modelos Animais de Doenças , Eritrócitos/parasitologia , Malária Falciparum/complicações , Malária Falciparum/patologia , Mefloquina/uso terapêutico , Proteína 1 de Superfície de Merozoito/administração & dosagem , Doenças dos Macacos/imunologia , Doenças dos Macacos/patologia , Parasitemia/tratamento farmacológico , Parasitemia/imunologia , Plasmodium falciparum/crescimento & desenvolvimentoRESUMO
BACKGROUND: Clinical symptoms of mixed-species malaria infections have been variously reported as both less severe and more severe than those of single-species infections. METHODS: Oral temperatures were taken from and blood slides were prepared for 2308 adults who presented at outpatient malaria clinics in Tak Province (Thailand) during May-August 1998, May-July 1999, and May-June 2001 with malaria infections diagnosed by 2 expert research microscopists, each of whom was blinded to the other's reports. RESULTS: In each year, temperatures of patients with mixed Plasmodium vivax-Plasmodium falciparum infections were higher than temperatures of patients with P. vivax or P. falciparum infections. In every mixed-species case, P. falciparum parasitemia was higher than P. vivax parasitemia, but patient temperature was not correlated with the parasitemia of either species or with the total parasitemia. CONCLUSIONS: Among adults who self-report to malaria clinics in western Thailand, patients with mixed P. vivax-P. falciparum infections have higher fevers than patients with single-species infections, a distinction that cannot be attributed to differences in parasitemia. This observation warrants more detailed investigations, spanning wider ranges of ages and transmission environments.
Assuntos
Febre/parasitologia , Malária/parasitologia , Adulto , Animais , Feminino , Humanos , Masculino , Plasmodium falciparum , Plasmodium vivaxRESUMO
A retrospective surveillance study was conducted to examine the micro-geographic variation of malaria incidence in three malaria-endemic communities in the Northern Peruvian Amazon. The annual malaria risk rate (per 100) ranged from 38% to 47% for Plasmodium vivax and from 15% to 18% for P. falciparum. Spatial clusters were found for P. vivax in Padre Cocha, Manacamiri, and Zungaro Cocha, and for P. falciparum only in Padre Cocha. Spatial-temporal clusters showed that the highest monthly number of P. vivax cases varied every year from December to March in 1996-1997 and from February to June in 1998-1999, and for P. falciparum from November to April in 1996-1997 and from January to April in 1998-1999. Our results suggest a constant presence of high-risk areas (hot spots) for malaria infection in periods with high or low malaria incidence. Modest targeted control efforts directed at identified high-risk areas may have significant impact on malaria transmission in this region.
Assuntos
Habitação , Malária/epidemiologia , Análise por Conglomerados , Feminino , Geografia , Humanos , Incidência , Malária Falciparum/epidemiologia , Malária Vivax/epidemiologia , Masculino , Peru/epidemiologia , Estudos Retrospectivos , Estações do Ano , Clima TropicalRESUMO
Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P. ovale malaria since the early 1950s, based on its ability to kill latent (hypnozoite) and developing liver stages of these parasites. There are three uses for primaquine in malaria: radical cure of established infection with P. vivax or P. ovale malaria; presumptive anti-relapse therapy (PART; terminal prophylaxis) in persons with extensive exposure to these parasites; and primary prophylaxis against all malaria species. All persons for whom primaquine is being considered must have a glucose-6-phosphate dehydrogenase (G6PD) enzyme level checked before use, and persons who have a deficiency of G6PD must not take primaquine for prophylaxis or PART. The recommended adult dose for PART based on clinical trials and expert opinion is 30 mg base daily for 14 days, started on return from a malarious region and overlapping with a blood schizonticide. The adult dose for primary prophylaxis is 30 mg daily begun 1 day before travel and continued for 7 days after return. This review will examine the evidence for these recommendations.
Assuntos
Antimaláricos/uso terapêutico , Malária/prevenção & controle , Primaquina/uso terapêutico , Adulto , Antimaláricos/efeitos adversos , Antimaláricos/farmacocinética , Centers for Disease Control and Prevention, U.S. , Criança , Ensaios Clínicos como Assunto , Contraindicações , Glucosefosfato Desidrogenase/metabolismo , Humanos , Malária/embriologia , Cooperação do Paciente , Recidiva , Estados UnidosRESUMO
Two expert research microscopists, each blinded to the other's reports, diagnosed single-species malaria infections in 2,141 adults presenting at outpatient malaria clinics in Tak Province, Thailand, and Iquitos, Peru, in May-August 1998, May-July 1999, and May-June 2001. Plasmodium vivax patients with gametocytemia had higher fever and higher parasitemia than those without gametocytemia; temperature correlated with parasitemia in the patients with gametocytemia. Plasmodium falciparum patients with gametocytemia had lower fever than those without gametocytemia, but similar parasitemia; temperature correlated with parasitemia in the patients without gametocytemia. Hematologic data in Thailand in 2001 showed lower platelet counts in P. vivax patients with gametocytemia than in the P. vivax patients without gametocytemia, whereas P. falciparum patients with gametocytemia had similar platelet counts but lower red blood cell counts, hemoglobin levels, hematocrit levels, and higher lymphocyte counts than patients without gametocytemia.
Assuntos
Doenças Endêmicas , Malária Falciparum/epidemiologia , Malária Vivax/epidemiologia , Parasitemia/epidemiologia , Adulto , Fatores Etários , Animais , Estudos Transversais , Contagem de Eritrócitos , Feminino , Febre , Hematócrito , Hemoglobinas/análise , Humanos , Contagem de Leucócitos , Malária Falciparum/parasitologia , Malária Vivax/parasitologia , Masculino , Parasitemia/parasitologia , Peru/epidemiologia , Tailândia/epidemiologiaRESUMO
AbstractIn February 2014, the Malaria Elimination Working Group, in partnership with the Peruvian Ministry of Health (MoH), hosted its first international conference on malaria elimination in Iquitos, Peru. The 2-day meeting gathered 85 malaria experts, including 18 international panelists, 23 stakeholders from different malaria-endemic regions of Peru, and 11 MoH authorities. The main outcome was consensus that implementing a malaria elimination project in the Amazon region is achievable, but would require: 1) a comprehensive strategic plan, 2) the altering of current programmatic guidelines from control toward elimination by including symptomatic as well as asymptomatic individuals for antimalarial therapy and transmission-blocking interventions, and 3) the prioritization of community-based active case detection with proper rapid diagnostic tests to interrupt transmission. Elimination efforts must involve key stakeholders and experts at every level of government and include integrated research activities to evaluate, implement, and tailor sustainable interventions appropriate to the region.
RESUMO
Infection with protozoan parasites of the genus Leishmania leads to a wide variety of clinical disease syndromes called leishmaniasis, or more appropriately the leishmaniases. The three major clinical syndromes are cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis. All three of these syndromes have been documented in returning travelers. This article focuses on cutaneous leishmaniasis with some comment on mucosal leishmaniasis.